Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | LCAT | P04180 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064297 | 1.00 | NR1H4 (0.39) | NR1H4HSD17B13MALT1CNR2PANK3 | |
| SCHEMBL32678098 | 0.87 | PANK3 (0.39) | NR1H4CNR2PANK3PPARGTRPV4 | |
| SCHEMBL19690232 | 0.87 | PANK3 (0.39) | NR1H4CNR2PANK3PPARGTRPV4 | |
| SCHEMBL32678099 | 0.87 | PANK3 (0.39) | NR1H4CNR2PANK3PPARGTRPV4 | |
| SCHEMBL29216000 | 0.83 | NR1H4 (0.54) | NR1H4HSD17B13 | |
| SCHEMBL30775154 | 0.83 | NR1H4 (0.54) | NR1H4HSD17B13 | |
| SCHEMBL19202590 | 0.81 | NR1H4 (0.46) | NR1H4HSD17B13HRH3 | |
| SCHEMBL19690343 | 0.81 | NR1H4 (0.44) | NR1H4TRPV4CHRM4 | |
| SCHEMBL19689487 | 0.80 | MALT1 (0.40) | NR1H4HSD17B13MALT1CNR2PANK3 | |
| SCHEMBL30064306 | 0.80 | MALT1 (0.40) | NR1H4HSD17B13MALT1CNR2PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4089072-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| EP-3587412-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981881-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885MALT1 2190/4885 |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885MALT1 2190/4885 |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885MALT1 2190/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885MALT1 2190/4885 |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885MALT1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.